bluebird bio Inc. (BLUE) announced after the close Tuesday that the National Institutes of Health Recombinant DNA Advisory Committee's completed its public review of the HGB-208 pediatric study protocol for bluebird bio's LentiGlobin BB305 product candidate in beta-thalassemia major. The committee recommended to delay initiation of the study in the United States for one to two years. The stock is now down 8.64 on 12K shares.
bluebird bio declined during the first hour of trade Tuesday, but recovered some ground in the early afternoon. Shares finished down by 1.98 at $186.63. The stock closed near the middle of a 3-week range at the highs of the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.